Neil Fanger
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$5.2MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $5.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 1, 2022 | NIH | SBIR Phase I A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | $613K | VIRTICI LLC |
| Feb 1, 2021 | NIH | SBIR Phase I A Novel LIGHT/TL1A Bispecific Antibody for the Treatment of Fibrotic Diseases | $299K | VIRTICI LLC |
| Jul 11, 2019 | NIH | SBIR Phase I A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients | $459K | VIRTICI LLC |
| Jul 1, 2018 | NIH | SBIR Phase I A Novel Tolerance Therapeutic for Treating Graves' Disease | $300K | VIRTICI LLC |
| Sep 15, 2017 | NIH | SBIR Phase I A Novel Tolerance Therapeutic for Treating Type Diabetes | $300K | VIRTICI LLC |
| Aug 2, 2017 | NIH | SBIR Phase I A Novel Tolerance inducing Probiotic Platform | $300K | VIRTICI LLC |
| Apr 24, 2017 | NIH | SBIR Phase II A Novel Tolerance Therapeutic for Treating Multiple Sclerosis | $2.0M | VIRTICI LLC |
| Aug 2, 2016 | NIH | SBIR Phase I A Novel Probiotic for the Treatment of Sjogren's Syndrome | $225K | VIRTICI LLC |
| Sep 30, 2015 | NIH | SBIR Phase I A Novel Therapeutic Peptide for Treating Stroke | $434K | VIRTICI LLC |
| Mar 1, 2015 | NIH | SBIR Phase I A Novel Tolerance Therapeutic for Treating Peanut Allergy | $319K | VIRTICI LLC |
Peer ranks
Federal funding#257
Awards as PI#128
Patents#273
Companies
- VIRTICI LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.